Ruxolitinib: A potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians

Therapeutic Advances in Hematology

Volumn 3, Issue 6, 2012, Pages 341-354

  Harrison, Claire ^a   Vannucchi, Alessandro M ^b  

^a GUY S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

JAKafi; janus kinase 2; myelofibrosis; myeloproliferative neoplasm; ruxolitinib

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BARICITINIB; BSK 805; CORTICOSTEROID; DANAZOL; ERYTHROPOIETIN; EVEROLIMUS; GANDOTINIB; GIVINOSTAT; HEMOGLOBIN; HYDROXYUREA; INC 424; INCB 16562; JANUS KINASE 1; JANUS KINASE 2; LENALIDOMIDE; LESTAURTINIB; MOMELOTINIB; N TERT BUTYL 3 [5 METHYL 2 [4 [2 (1 PYRROLIDINYL)ETHOXY]PHENYLAMINO] 4 PYRIMIDINYLAMINO]BENZENESULFONAMIDE; OBATOCLAX; PACRITINIB; PANOBINOSTAT; PEGINTERFERON ALPHA2A; POMALIDOMIDE; R 723; RUXOLITINIB; THALIDOMIDE; UNCLASSIFIED DRUG; XL 019;

ABDOMINAL DISCOMFORT; AGE; ANEMIA; ANXIETY DISORDER; ASTHENIA; BLAST CELL; COMBINATION CHEMOTHERAPY; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ECCHYMOSIS; ERYTHROCYTE TRANSFUSION; EXTRAMEDULLARY HEMATOPOIESIS; FATIGUE; FEVER; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; IC 50; INSOMNIA; KARYOTYPE; LEUKOCYTE COUNT; MUSCULOSKELETAL PAIN; MYELOFIBROSIS; NEUTROPENIA; NIGHT SWEAT; OPTIMAL DRUG DOSE; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; SPLENOMEGALY; STEROID THERAPY; SURVIVAL TIME; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT WITHDRAWAL;

EID: 84993683627     PISSN: 20406207     EISSN: 20406215     Source Type: Journal    
DOI: 10.1177/2040620712459746     Document Type: Review

References (85)

1. Abdel-Wahab O. Pardanani A. Rampal R. Lasho T. Levine R. Tefferi A. (2011) DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms. Leukemia 25: 1219–1220.
2. Bacigalupo A. Soraru M. Dominietto A. Pozzi S. Geroldi S. van Lint M. et al. (2010) Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type. Bone Marrow Transplant 45: 458–463.
3. Baffert F. Regnier C. de Pover A. Pissot-Soldermann C. Tavares G. Blasco F. et al. (2010) Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805. Mol Cancer Ther 9: 1945–1955.
4. Barosi G. Birgegard G. Finazzi G. Griesshammer M. Harrison C. Hasselbalch H. et al. (2009) Response criteria for essential thrombocythemia and polycythemia vera: result of a European Leukemianet Consensus Conference. Blood 113: 4829–4833.
5. Barosi G. Mesa R. Thiele J. Cervantes F. Campbell P. Verstovsek S. et al. (2008) Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 22: 437–438.
6. Baxter E. Scott L. Campbell P. East C. Fourouclas N. Swanton S. et al. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365: 1054–1061.
7. Brucker P. Yost K. Cashy J. Webster K. Cella D. (2005) General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General (Fact-G). Eval Health Prof 28: 192–211.
8. Bumm T. Elsea C. Corbin A. Loriaux M. Sherbenou D. Wood L. et al. (2006) Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res 66: 11156–11165.
9. Carbuccia N. Murati A. Trouplin V. Brecqueville M. Adelaide J. Rey J. et al. (2009) Mutations of ASxL 1 gene in myeloproliferative neoplasms. Leukemia 23: 2183–2186.
10. Cervantes F. Alvarez-Larrán A. Domingo A. Arellano-Rodrigo E. Montserrat E. (2005) Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients. BrJ Haemtaol 129: 771–775.
11. Cervantes F. Alvarez-Larran A. Hernandez-Boluda J. Sureda A. Granell M. Vallansot R. et al. (2006) Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid metaplasia. Br J Haematol 134: 184–186.
12. Cervantes F. Dupriez B. Pereira A. Passamonti F. Reilly J. Morra E. et al. (2009) New prognostic scoring system for primary myelofibrosis based on a study of the international Working Group for Myelofibrosis Research and Treatment. Blood 113: 2895–2901.
13. Dameshek W. (1951) Some speculations on the myeloproliferative syndromes. Blood 6: 372–375.
14. Danilov A. Relias V. Feeney D. Miller K. (2009) Decitabine is an effective treatment of idiopathic myelofibrosis. Br J Haematol 145: 131–132.
15. Deangelo D. Tefferi A. Fiskus W. Mesa R. Paley C. Wadleigh M. et al. (2010) A phase II trial of panobinostat, an orally available deacetylase inhibitor (DACI), in patients with primary myelofibrosis (PMF), post essential Thrombocythemia (ET), and post polycythemia vera (PV) myelofibrosis. ASH Annual Meeting Abstracts 116: 630A.
16. Delhommeau F. Dupont S. Della Valle V. James C. Trannoy S. Masse A. et al. (2009) Mutation in TET 2 in myeloid cancers. N Engl J Med 360: 2289–2301.
17. Eghtedar A. Verstovsek S. Estrov Z. Burger J. Cortes J. Bivins C. et al. (2012) Phase II study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including post myeloproliferative neoplasms (MPN) acute myeloid leukemia (AML). Blood 119: 4614–4618.
18. Ernst T. Chase A. Score J. Hidalgo-Curtis C. Bryant C. Jones A. et al. (2010) Inactivating mutations of the histone methyltransferase gene EZH 2 in myeloid disorders. Nat Genet 42: 722–726.
19. Florensa L. Bellosillo B. Arenillas L. Ma L. Walgren R. Alvarez A. et al. (2010) LY2784544, a novel JAK2 inhibitor, decreases in vitro growth of hematopoietic human progenitors from JAK2V617F positive polycythemia vera patients. ASH Annual Meeting Abstracts 116: 5054.
20. Fridman J. Scherle P. Collins R. Burn T. Li Y. Li J. et al. (2010) Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol 184: 5298–5307.
21. Gangat N. Caramazza D. Vaidya R. George G. Begna K. Schwager S. et al. (2011) DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 29: 392–397.
22. Grand F.H. Hidalgo-Curtis C.E. Ernst T. Zoi K. Zoi C. McGuire C. et al. (2009) Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 113 (24):6182–6192.
23. Green A. Beer P. (2010) Somatic mutations of IDH 1 and IDH 2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med 362: 369–370.
24. Guglielmelli P. Barosi G. Rambaldi A. Marchioli R. Masciulli A. Tozzi L. et al. (2011 a) Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1 / 2 study in patients with myelofibrosis. Blood 118: 2069–2076.
25. Guglielmelli P. Biamonte F. Score J. Hidalgo-Curtis C. Cervantes F. Maffioli M. et al. (2011 b) EZH2 mutational status predicts poor survival in myelofibrosis. Blood 118: 5227–5234.
26. Guglielmelli P. Pancrazzi A. Bergamaschi G. Rosti V. Villani L. Antonioli E. et al. (2007) Anaemia characterises patients with myelofibrosis harbouring MPL mutation. Br J Haematol 137: 244–247.
27. Ha J. Jeon D. (2011) Possible new LNK mutations in myeloproliferative neoplasms. Am J Hematol 86: 866–868.
28. Harrison C. Kiladjian J. Al-Ali H. Gisslinger H. Waltzman R. Stalbovskaya V. et al. (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366: 787–798.
29. Harrison C. Kiladjian J. Gisslinger H. Niederwieser D. Passamonti F. Waltzman R. et al. (2011) Ruxolitinib provides reductions in splenomegaly across subgroups: an analysis of spleen response in the COMFORT-II study. Blood 118: abstract 279.
30. Hart S. Goh K. Novotny-Diermayr V. Hu C. Hentze H. Tan Y. et al. (2011) SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. Leukemia 25: 1751–1759.
31. Harutyunyan A. Klampfl T. Cazzola M. Kralovics R. (2011) P53 Lesions in leukemic transformation. N Engl J Med 364: 488–490.
32. Hexner E. Goldberg J. Prchal J. et al. (2009) A multicenter, open label phase I / II study of CEP 701 (lestaurtinib) in adults with myelofibrosis; a report on phase I: a study of the Myeloproliferative Disorders Research Consortium. Blood 114: abstract 754.
33. Hexner E. Serdikoff C. Jan M. Swider C. Robinson C. Yang S. et al. (2008) Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 111: 5663–5671.
34. Jager R. Gisslinger H. Passamonti F. Rumi E. Berg T. Gisslinger B. et al. (2010) Deletions of the transcription factor ikaros in myeloproliferative neoplasms. Leukemia 24: 1290–1298.
35. James C. Ugo V. Le Couedic J. Staerk J. Delhommeau F. Lacout C. et al. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434: 1144–1148.
36. Jiang J. Ghoreschi K. Deflorian F. Chen Z. Perreira M. Pesu M. et al. (2008) Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550). J Med Chem 51: 8012–8018.
37. Kiladjian J. Cassinat B. Chevret S. Turlure P. Cambier N. Roussel M. et al. (2008) Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 112: 3065–3072.
38. Kralovics R. Passamonti F. Buser A. Teo S. Tiedt R. Passweg J. et al. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352: 1779–1790.
39. Kralovics R. Passamonti F. Buser A. Teo S. Tiedt R. Passweg J. et al. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352: 1779–1790.
40. Kuter D. (2010) Biology and chemistry of thrombopoietic agents. Semin Hematol 47: 243–248.
41. Lacout C. Pisani D. Tulliez M. Gachelin F. Vainchenker W. Villeval J. (2006) JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 108: 1652–1660.
42. Levine R. Wadleigh M. Cools J. Ebert B. Wernig G. Huntly B. et al. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7: 387–397.
43. Liu P. Caulder E. Li J. Waeltz P. Margulis A. Wynn R. et al. (2009) Combined inhibition of Janus kinase 1 / 2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity. Clin Cancer Res 15: 6891–6900.
44. Lu M. Wang J. Li Y. Berenzon D. Wang X. Mascarenhas J. et al. (2010) Treatment with the BCL-XL inhibitor ABT-737 in combination with interferon alpha specifically targets JAK2V617F-positive polycythemia vera hematopoietic progenitor cells. Blood 116: 4284–4287.
45. Ma L. Zhao B. Walgren R. Clayton J. Blosser W. Burkholder T. et al. (2010) Efficacy of LY2784544, a small molecule inhibitor selective for mutant JAK2 kinase, in JAK2V617F-induced hematologic malignancy models. ASH Annual Meeting Abstracts 116: 4087.
46. Marubayashi S. Koppikar P. Taldone T. Abdel-Wahab O. West N. Bhagwat N. et al. (2010) HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. J Clin Invest 120: 3578–3593.
47. McLornan D. Mead A. Jackson G. Harrison C. (2012) Allogeneic stem cell transplantation for myelofibrosis in 2012. Br J Haematol 157: 413–425.
48. Mesa R. Kantarjian H. Tefferi A. Dueck A. Levy R. Vaddi K. et al. (2011) Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement. Cancer 117: 4869–4877.
49. Mesa R. Schwager S. Radia D. Cheville A. Hussein K. Niblack J. et al. (2009) The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leukemia Res 33: 1199–1203.
50. Mesa R. Verstovsek S. Rivera C. Pardanani A. Hussein K. Lasho T. et al. (2009) 5-Azacitidine has limited therapeutic activity in myelofibrosis. Leukemia 23: 180–182.
51. Mesa R. Yao X. Cripe L. Li C. Litzow M. Paietta E. et al. (2010) Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. Blood 116: 4436–4438.
52. Oh S.T. Simonds E.F. Jones C. Hale M.B. Goltsev Y. Gibbs K.D. Jr. et al. (2010) Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 116 (6):988–992.
53. Paquette R. Sokal L. Shah N. et al. (2008) A phase I study of Xl019, a selective JAK2 inhibitor, in patients with polycythemia vera. Blood 112: abstract 2810.
54. Pardanani A. Gotlib J. Gupta V. Roberts A. Wadleigh M. Sirhan S. et al. (2011 a) An expanded multicenter phase I / II study of CYT387, a JAK-1/2 inhibitor for the treatment of myelofibrosis. ASH Annual Meeting Abstracts 118: 3849.
55. Pardanani A. Gotlib J. Jamieson C. Cortes J. Talpaz M. Stone R. et al. (2011 b) Sar302503: Interim Safety, efficacy and long-term impact on JAK2V617F allele burden in a phase I / II study in patients with myelofibrosis. ASH Annual Meeting Abstracts 118: 3838.
56. Pardanani A. Gotlib J. Jamieson C. Cortes J. Talpaz M. Stone R. et al. (2009 a) A phase I study of TG101348, a selective JAK2 inhibitor, in myelofibrosis: clinical response is accompanied by significant reduction in JAK2V617F allele burden. Blood 114: abstract 755.
57. Pardanani A. Guglielmelli P. Lasho T. Pancrazzi A. Finke C. Vannucchi A. et al. (2011 c) Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients. Leukemia 25: 1834–1839.
58. Pardanani A. Lasho T. Finke C. Oh S. Gotlib J. Tefferi A. (2010) LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia 24: 1713–1718.
59. Pardanani A. Lasho T. Smith G. Burns C. Fantino E. Tefferi A. (2009 b) CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia 23: 1441–1445.
60. Parikh S. Kantarjian H. Schimmer A. Walsh W. Asatiani E. El-Shami K. et al. (2010) Phase II study of obatoclax mesylate (GX15–070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leuk 10: 285–289.
61. Passamonti F. Cervantes F. Vannucchi A. Morra E. Rumi E. Pereira A. et al. (2010) A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 115: 1703–1708.
62. Passamonti F. Elena C. Schnittger S. Skoda R. Green A. Girodon F. et al. (2011) Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood 117: 2813–2816.
63. Pikman Y. Lee B. Mercher T. McDowell E. Ebert B. Gozo M. et al. (2006) MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 3: e270.
64. Quintas-Cardama A. Vaddi K. Liu P. Manshouri T. Li J. Scherle P. et al. (2010) Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115: 3109–3117.
65. Rambaldi A. Dellacasa C. Finazzi G. Carobbio A. Ferrari M. Guglielmelli P. et al. (2010) A pilot study of the histone-deacetylase inhibitor givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol 150: 446–455.
66. Santos F. Kantarjian H. Jain N. Manshouri T. Thomas D. Garcia-Manero G. et al. (2010) Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera / essential thrombocythemia myelofibrosis. Blood 115: 1131–1136.
67. Scott L. Tong W. Levine R. Scott M. Beer P. Stratton M. et al. (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356: 459–468.
68. Shah N. Olszynski P. Sokal L. Verstovsek S. Hoffman R. List A. et al. (2008) A phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis, post-polycythemia vera, or post-essential thrombocythemia myelofibrosis. Blood 112: abstract 98.
69. Shide K. Kameda T. Markovtsov V. et al. (2009) Efficacy of R723, a potent and selective JAK2 inhibitor, in JAK2V617F-induced murine MPD model. Blood 11: abstract 3897.
70. Tefferi A. Barosi G. Mesa R. Cervantes F. Deeg H. Reilly J. et al. (2006) International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 108: 1497–1503.
71. Tefferi A. Litzow M. Pardanani A. (2011) Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med 365: 1455–1457.
72. Tefferi A. Verstovsek S. Barosi G. Passamonti F. Roboz G. Gisslinger H. et al. (2009) Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol 27: 4563–4569.
73. Tiedt R. Hao-Shen H. Sobas M. Looser R. Dirnhofer S. Schwaller J. et al. (2008) Ratio of mutant JAK2-V617F to wild-type JAK2 determines the MPD phenotypes in transgenic mice. Blood 111: 3931–3940.
74. Tyner J. Bumm T. Deininger J. Wood L. Aichberger K. Loriaux M. et al. (2010) CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood 115: 5232–5240.
75. Vannucchi A. (2010) From palliation to targeted therapy in myelofibrosis. N Engl J Med 363: 1180–1182.
76. Vannucchi A. Antonioli E. Guglielmelli P. Pancrazzi A. Guerini V. Barosi G. et al. (2008) Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood 112: 844–847.
77. Vannucchi A. Guglielmelli P. Tefferi A. (2009) Advances in understanding and management of myeloproliferative neoplasms. CA Cancer J Clin 59: 171–191.
78. Verstovsek S. Kantarjian H. Estrov Z. Cortes J. Thomas D. Kadia T. et al. (2012 a) Long term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood 120: 1202–1209.
79. Verstovsek S. Kantarjian H. Mesa R. Pardanani A. Cortes-Franco J. Thomas D. et al. (2010 a) Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363: 1117–1127.
80. Verstovsek S. Mesa R. Gotlib J. Levy R. Gupta V. Dipersio J. et al. (2012 b) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366: 799–807.
81. Verstovsek S. Mesa R. Gotlib J. Levy R. Gupta V. Dipersio J. et al. (2011) Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: results from COMFORT-I clinically relevant abstract. Blood 118.
82. Verstovsek S. Passamonti F. Rambaldi A. Barosi G. Rosen P. Levy R. et al. (2010 b) Durable responses with the JAK1/JAK2 inhibitor, INCB018424, in patients with polycythemia vera (PV) and essential thrombocythemia (ET) refractory or intolerant to hydroxyurea (HU). ASH Annual Meeting Abstracts 116: 313.
83. Wernig G. Kharas M. Okabe R. Moore S. Leeman D. Cullen D. et al. (2008) Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 13: 311–320.
84. Wernig G. Mercher T. Okabe R. Levine R. Lee B. Gilliland D. (2006) Expression of JAK2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 107: 4274–4281.
85. Zaleskas V. Krause D. Lazarides K. Patel N. Hu Y. Li S. et al. (2006) Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2V617F. PloS ONE 1: e18.